Drug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, Helsinki, 00014, Finland.
Department of Orthopaedics, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China.
Nat Commun. 2022 Mar 10;13(1):1262. doi: 10.1038/s41467-022-28787-7.
Drug delivery systems with high content of drug can minimize excipients administration, reduce side effects, improve therapeutic efficacy and/or promote patient compliance. However, engineering such systems is extremely challenging, as their loading capacity is inherently limited by the compatibility between drug molecules and carrier materials. To mitigate the drug-carrier compatibility limitation towards therapeutics encapsulation, we developed a sequential solidification strategy. In this strategy, the precisely controlled diffusion of solvents from droplets ensures the fast in-droplet precipitation of drug molecules prior to the solidification of polymer materials. After polymer solidification, a mass of drug nanoparticles is embedded in the polymer matrix, forming a nano-in-micro structured microsphere. All the obtained microspheres exhibit long-term storage stability, controlled release of drug molecules, and most importantly, high mass fraction of therapeutics (21.8-63.1 wt%). Benefiting from their high drug loading degree, the nano-in-micro structured acetalated dextran microspheres deliver a high dose of methylprednisolone (400 μg) within the limited administration volume (10 μL) by one single intrathecal injection. The amount of acetalated dextran used was 1/433 of that of low drug-loaded microspheres. Moreover, the controlled release of methylprednisolone from high drug-loaded microspheres contributes to improved therapeutic efficacy and reduced side effects than low drug-loaded microspheres and free drug in spinal cord injury therapy.
载药系统中高浓度的药物可以最大限度地减少赋形剂的使用,减少副作用,提高治疗效果和/或提高患者的顺应性。然而,工程化此类系统极具挑战性,因为其载药能力本质上受到药物分子与载体材料之间相容性的限制。为了缓解药物-载体相容性限制对治疗学封装的影响,我们开发了一种顺序固化策略。在该策略中,溶剂从液滴中的精确控制扩散确保了在聚合物材料固化之前,药物分子在液滴内快速沉淀。聚合物固化后,大量药物纳米颗粒嵌入聚合物基质中,形成纳米-微结构化微球。所有获得的微球均表现出长期储存稳定性、药物分子的控制释放,最重要的是,具有高治疗药物质量分数(21.8-63.1wt%)。受益于其高载药程度,纳米-微结构化的乙酰化葡聚糖微球通过单次鞘内注射在有限的给药体积(10μL)内递送高剂量的甲基强的松龙(400μg)。所用乙酰化葡聚糖的量是低载药微球的 1/433。此外,高载药微球中甲基强的松龙的控制释放有助于提高治疗效果,并减少脊髓损伤治疗中与低载药微球和游离药物相比的副作用。